FDA warning letter to Boothwyn Pharmacy over compounded GLP-1 conditions

The FDA issued a warning letter on January 16, 2026, to Boothwyn Pharmacy, LLC, a state-licensed 503A compounding pharmacy, citing violations tied to its GLP-1 and other compounded products. The letter, which was not made public until February 10, described insanitary conditions and products that did not comply with their stated strength, quality or purity ^[1].

Those are serious findings under the Federal Food, Drug, and Cosmetic Act. "Strength, quality or purity" noncompliance means a compounded drug may not contain what its label says it contains. Insanitary conditions refer to the physical environment in which sterile or non-sterile drugs are prepared — a central concern for injectable products, which bypass the body's normal barriers to contamination ^[1].

If a pharmacy does not address the cited problems in a satisfactory or timely way, the FDA can take further action without issuing another warning, including product recalls, seizure of products, injunctions and criminal actions that could carry civil monetary penalties. The agency can also refer the matter to state regulators, which have authority over the licenses of the pharmacy and its pharmacists ^[1]. Whether Boothwyn has responded, and what corrective steps it has taken, has not been reported.

A broader shift in FDA posture

The Boothwyn letter landed in the middle of a rapid escalation. On September 16, 2025, the FDA issued more than 55 warning letters to online sellers of compounded versions of semaglutide (the molecule in Wegovy) and tirzepatide (the molecule in Zepbound), focused mainly on misleading direct-to-consumer advertising ^[1]. Attorneys writing in Pharmacy Times described that round as feeling like "compliance theater" at the time, noting that telehealth providers and compounders largely kept advertising and producing patient-specific versions or copies of the branded drugs ^[1].

That changed on February 6, 2026, when the FDA announced it would move to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products and to combat misleading marketing. The agency warned that entities manufacturing, distributing or marketing unapproved compounded GLP-1 products "should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction" ^[1]. The FDA named telehealth company Hims & Hers in that announcement ^[1].

Three days later, on February 9, 2026, Novo Nordisk sued Hims & Hers for infringing US Patent No. 8,129,343 with compounded semaglutide products. Novo alleged the company had continued to "mass-compound injectable versions" of Wegovy "made with inauthentic API" and marketed them as comparable in safety and effectiveness to Wegovy, "putting patient health and well-being at risk" ^[1]. Hims & Hers had announced a commercial launch of a compounded semaglutide tablet on February 5, 2026 — after Novo Nordisk launched its FDA-approved once-daily semaglutide tablet in January 2026 ^[1].

Why it matters for patients

Many people turned to compounded GLP-1s because of cost or supply. This letter is a concrete example of what regulators say can go wrong: a compounded vial may not deliver the dose on the label, and the conditions where it was made may not meet federal standards ^[1]. Compounded drugs are not FDA-approved, and 503A pharmacies are exempt from some labeling rules and from the current good manufacturing practice requirements that apply to approved drugs and to 503B outsourcing facility products — though they remain subject to FDA jurisdiction under the FD&C Act ^[1].

Pricing context has shifted too. TrumpRx launched February 5, 2026, listing monthly cash prices for semaglutide tablets at $149 to $299 (versus $1,349), semaglutide injections at $199 to $349 (versus $1,349), and tirzepatide injections at $299 to $449 (versus $1,087) ^[1].

What happens next

Some 503A pharmacies are expected to argue they are doing legitimate patient-specific compounding under physician orders, often by adding ingredients meant to reduce side effects or customizing doses — a large share of those prescriptions written by telehealth prescribers ^[1]. FDA's 2018 guidance on "essentially a copy" compounding allows an exception when a prescriber documents that the compounded drug produces a significant difference for a specific patient, and the agency said it generally does not intend to question such documented determinations ^[1]. How the FDA applies that standard to GLP-1s has not yet been resolved.